Craig C. Hopkinson

Insider Reports History

Location: 852 Winter Street, Waltham, MA
Signature: /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
All insider transactions: Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Craig C. Hopkinson:

Stock	Role	Class	Num Shares	Value	Price $	Report Date	Ownership
Alkermes plc.	EVP R&D, Chief Medical Officer	Ordinary Shares	77.7K	$2.7M	$34.80	Feb 26, 2025	Direct
Alkermes plc.	EVP R&D, Chief Medical Officer	Employee Stock Option (Right to Buy)	64K			Feb 19, 2025	Direct
Alkermes plc.	EVP R&D, Chief Medical Officer	Restricted Stock Unit Award	20.6K			Feb 26, 2025	Direct
ALBIREO PHARMA, INC.	Director	Restricted Stock Units	0			Mar 2, 2023	Direct

Previous1Next

Showing 1 to 4 of 4 entries

Insider Reports Filed by Craig C. Hopkinson

Symbol	Company	Period	Transactions	Value $	Form Type	Date Filed	Role
ALKS	Alkermes plc.	Feb 26, 2025	3	-$106K	4	Feb 28, 2025	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 22, 2025	6	-$313K	4	Feb 25, 2025	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 18, 2025	5	-$142K	4	Feb 20, 2025	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 12, 2025	12	-$3.59M	4	Feb 14, 2025	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 6, 2025	2	-$473K	4	Feb 7, 2025	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Jan 30, 2025	9	-$1.07M	4	Jan 31, 2025	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Dec 9, 2024	9	-$849K	4	Dec 9, 2024	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Dec 5, 2024	1	-$290K	4	Dec 5, 2024	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Dec 4, 2024	1	-$442K	4	Dec 4, 2024	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Nov 11, 2024	3	-$912K	4	Nov 12, 2024	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Nov 6, 2024	1	-$309K	4	Nov 6, 2024	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 23, 2024	5	-$101K	4	Feb 27, 2024	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 22, 2024	3	-$158K	4	Feb 23, 2024	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 18, 2024	6	-$266K	4	Feb 21, 2024	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 8, 2024	13	$101K	4	Feb 12, 2024	EVP R&D, Chief Medical Officer
ALBO	ALBIREO PHARMA, INC.	Mar 2, 2023	1	$0	4	Mar 2, 2023	Director
ALKS	Alkermes plc.	Feb 22, 2023	5	-$148K	4	Feb 24, 2023	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 18, 2023	11	-$449K	4	Feb 22, 2023	EVP R&D, Chief Medical Officer
ALBO	ALBIREO PHARMA, INC.	Dec 1, 2022	0	$0	3	Dec 5, 2022	Director
ALBO	ALBIREO PHARMA, INC.	Dec 1, 2022	1	$0	4	Dec 5, 2022	Director
ALKS	Alkermes plc.	Feb 23, 2022	1	-$297K	4	Feb 24, 2022	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 18, 2022	12	-$272K	4	Feb 23, 2022	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Feb 16, 2022	3	-$28.6K	4	Feb 17, 2022	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Sep 14, 2021	2	-$173K	4	Sep 16, 2021	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Jun 9, 2021	1	-$21.7K	4	Jun 11, 2021	EVP R&D, Chief Medical Officer
ALKS	Alkermes plc.	Jun 7, 2021	3	-$8.65K	4	Jun 8, 2021	EVP R&D, Chief Medical Officer